Australia To Fund Mekinist, Xalkori But More Evidence Will Be Needed
This article was originally published in Scrip
Executive Summary
In another example of reimbursement agencies agreeing to pay for expensive new drugs in exchange for a commitment to provide more evidence of real clinical value, two major new anticancers from Novartis and Pfizer have been recommended for funding by the Australian Pharmaceutical Benefits Scheme under managed entry schemes. The agreements include a commitment to provide more convincing data with the possibility of a price cut if the terms of the schemes are not met.